Updated COVID-19 vaccines targeting XFG, a JN.1-lineage SARS-CoV-2 strain, have been approved for the 2026-27 vaccination season in key markets. In the United States, the FDA approved products from Moderna, Pfizer, BioNTech, Sanofi and Novavax, while Novavax's partners Sanofi and Takeda secured approvals for the protein-based, non-mRNA Nuvaxovid vaccine in markets including the U.S., European Union and Japan. Eligibility remains focused on adults 65 and older and, depending on the product, younger people with qualifying underlying conditions. The narrower market leaves demand below pandemic-era levels, but the approvals could support seasonal revenue as the fall respiratory-virus season approaches. Investors will watch whether XFG-targeted vaccines generate stronger demand.